LLY · 10-Q · 2026Q3 · Full report

Revenue Performance and Mix

ELI LILLY & Co · 2026-10-29 · Importance 68 · Surprise 56 · Matches filing data

Revenue was $24.397 billion in the third quarter of 2026, up approximately 39% from $17.601 billion, and $67.170 billion for the first nine months, up approximately 46% from $45.887 billion. Third-quarter U.S. revenue was $15.136 billion versus $11.300 billion, while revenue outside the U.S. was $9.261 billion versus $6.301 billion; nine-month revenue was $41.668 billion in the U.S. and $25.502 billion outside the U.S. Nine-month Mounjaro revenue rose to $29.328 billion from $15.556 billion, and Zepbound revenue rose to $14.440 billion from $9.281 billion. Revenue growth was driven primarily by increased volume, while lower realized prices—especially for Mounjaro and Zepbound—partially offset volume growth; outside the U.S., lower prices primarily reflected Mounjaro's inclusion on China's NRDL.

Key facts

• Revenue for the three months ended September 30, 2026 was $24,397 million, compared with $17,601 million in 2025; revenue for the nine months ended September 30, 2026 was $67,170 million, compared with $45,887 million in 2025. source
• U.S. revenue for the three months ended September 30, 2026 was $15,136 million, compared with $11,300 million in 2025; nine-month U.S. revenue was $41,668 million, compared with $30,604 million. source
• In the U.S., Mounjaro revenue increased 41% and 47% during the three and nine months ended September 30, 2026, respectively, reflecting strong demand partly offset by lower realized prices. source
• In the U.S., Zepbound revenue increased 48% and 54% during the three and nine months ended September 30, 2026, respectively, primarily due to strong demand partly offset by lower realized prices. source
• Revenue growth in the three and nine months ended September 30, 2026 was primarily driven by Mounjaro and Zepbound, with increased volume partly offset by lower realized prices. source

Impact estimates